Festus O. Ibe
Research Subjects
Festus O. Ibe has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Alero Ann Roberts
Institute of Child Health and Primary Care, College of Medicine, University of Lagos, Lagos, Nigeria
1 shared publication Atogwe Irhoboudu
Division of Hospital Medicine, Jefferson Einstein Philadelphia Hospital
1 shared publication- Chibuzor Franklin Ogamba
University of Oxford
1 shared publication Chidiebube Ugwu
Department of Medicine, Jefferson Einstein Philadelphia Hospital
1 shared publicationEmmanuel Otabor
Department of Medicine, Jefferson Einstein Philadelphia Hospital
1 shared publicationFuhad M. Jeje
Lagos State University College of Medicine
1 shared publication
Latest Publications
- Open Access
Beta-Blocker Use After Pulmonary Embolism in Patients with Cancer: A Real-World Propensity-Matched Study
Background Patients with active malignancy are at heightened risk for pulmonary embolism (PE), yet the prognostic implications of initiating beta-blocker (BB) therapy after PE in this population remain poorly characterized. Given the frequent coexistence of cardiovascular comorbidities, clarifying the safety profile of BB use post-PE in cancer patients is of clinical importance. Methods We conducted a retrospective cohort study using the TriNetX Global Health Research Network, a federated database aggregating de-identified electronic health records from over 85 health systems. Adults with active cancer and a new diagnosis of acute PE between January 1, 2015, and May 1, 2024, were included. Patients who received a BB within 30 days of PE diagnosis were assigned to the BB cohort; those who did not formed the comparator group. Propensity score matching (1:1, greedy nearest-neighbor, caliper = 0.01) was applied across baseline covariates. The primary outcome was 5-year all-cause mortality. Secondary outcomes included ICU admission, hospitalization, and incident heart failure. Patients with pre-index occurrence of the outcome were excluded from each respective analysis. Time-to-event analyses began on day 1 post-index using Kaplan-Meier curves and Cox proportional hazards models. Effect estimates were reported as absolute risk differences, odds ratios (OR), risk ratios (RR), and hazard ratios (HR), all with 95% confidence intervals (CI). Results Among 242,034 eligible patients, 19,948 received a beta-blocker within 30 days of PE diagnosis. After matching, 19,743 patients were retained in each cohort with excellent covariate balance (all post-match standardized mean differences Conclusion Our study that showed early beta-blocker use was associated with significantly increased risk of all-cause mortality and multiple adverse clinical outcomes. While rigorous propensity score matching was employed, unmeasured confounding and indication bias remain possible. These findings underscore the need for prospective studies to define the role—and risk—of beta-blocker therapy following thromboembolic events in oncology populations.
Open AccessBeta-Blocker Use After Pulmonary Embolism in Patients with Cancer: A Real-World Propensity-Matched Study
Background Patients with active malignancy are at heightened risk for pulmonary embolism (PE), yet the prognostic implications of initiating beta-blocker (BB) therapy after PE in this population remain poorly characterized. Given the frequent coexistence of cardiovascular comorbidities, clarifying the safety profile of BB use post-PE in cancer patients is of clinical importance. Methods We conducted a retrospective cohort study using the TriNetX Global Health Research Network, a federated database aggregating de-identified electronic health records from over 85 health systems. Adults with active cancer and a new diagnosis of acute PE between January 1, 2015, and May 1, 2024, were included. Patients who received a BB within 30 days of PE diagnosis were assigned to the BB cohort; those who did not formed the comparator group. Propensity score matching (1:1, greedy nearest-neighbor, caliper = 0.01) was applied across baseline covariates. The primary outcome was 5-year all-cause mortality. Secondary outcomes included ICU admission, hospitalization, and incident heart failure. Patients with pre-index occurrence of the outcome were excluded from each respective analysis. Time-to-event analyses began on day 1 post-index using Kaplan-Meier curves and Cox proportional hazards models. Effect estimates were reported as absolute risk differences, odds ratios (OR), risk ratios (RR), and hazard ratios (HR), all with 95% confidence intervals (CI). Results Among 242,034 eligible patients, 19,948 received a beta-blocker within 30 days of PE diagnosis. After matching, 19,743 patients were retained in each cohort with excellent covariate balance (all post-match standardized mean differences Conclusion Our study that showed early beta-blocker use was associated with significantly increased risk of all-cause mortality and multiple adverse clinical outcomes. While rigorous propensity score matching was employed, unmeasured confounding and indication bias remain possible. These findings underscore the need for prospective studies to define the role—and risk—of beta-blocker therapy following thromboembolic events in oncology populations.
- Open Access
- 20 September 2023
- Published by Springer Nature in Research Square
Preparedness of Nigerian Medical Students for an Era of Precision Medicine – A Cross-sectional Survey in Lagos, Nigeria.
Background The increasing advances in precision medicine in Nigeria suggest improving genomics education and competency among healthcare practitioners to facilitate clinical translation. Due to the scarcity of research in this area, this study aimed to assess Nigerian medical students' preparedness to integrate precision medicine into their clinical practice. Methods This was an institution-based cross-sectional study of 300 medicine and surgery students in their clinical years attending the two fully accredited colleges of medicine in Lagos, Nigeria, between April and October 2022 using an adapted tool administered via Google Forms. The survey assessed awareness, perceived knowledge, ability and attitudes towards precision medicine, ethical concerns, and perceptions about their education in precision medicine. Multivariate linear regression models were used to assess factors associated with students’ perceived knowledge, ability and attitudes. Results Awareness of genomic medicine terminology was high (92.0%). Respondents had above-average median perceived knowledge, ability and attitude scores. Higher level in medical school was independently associated with lower perceived knowledge (ptrend = 0.003) and ability (ptrend = 0.005) scores, and perceived knowledge score was independently associated with a higher perceived ability score (β: 0.76 95%CI: 0.67, 0.84; ptrend = 0.04). The respondents mostly indicated concerns about government and corporate bodies' misuse of genomic data (35.7%) and the widening of socioeconomic disparities (34.0%). Although 65.0% of the respondents thought it important to learn about precision medicine, only 11.3% felt that their education had adequately prepared them for precision medicine, knew who to ask questions regarding genomic testing (10.7%) and felt their professors had encouraged the use of precision medicine (10.3%). Conclusion Our findings highlight gaps in preparedness for precision medicine and a need to improve precision medicine education among Nigerian medical students.
- 20 September 2023
- Published by Springer Nature in Research Square
Open AccessPreparedness of Nigerian Medical Students for an Era of Precision Medicine – A Cross-sectional Survey in Lagos, Nigeria.
Background The increasing advances in precision medicine in Nigeria suggest improving genomics education and competency among healthcare practitioners to facilitate clinical translation. Due to the scarcity of research in this area, this study aimed to assess Nigerian medical students' preparedness to integrate precision medicine into their clinical practice. Methods This was an institution-based cross-sectional study of 300 medicine and surgery students in their clinical years attending the two fully accredited colleges of medicine in Lagos, Nigeria, between April and October 2022 using an adapted tool administered via Google Forms. The survey assessed awareness, perceived knowledge, ability and attitudes towards precision medicine, ethical concerns, and perceptions about their education in precision medicine. Multivariate linear regression models were used to assess factors associated with students’ perceived knowledge, ability and attitudes. Results Awareness of genomic medicine terminology was high (92.0%). Respondents had above-average median perceived knowledge, ability and attitude scores. Higher level in medical school was independently associated with lower perceived knowledge (ptrend = 0.003) and ability (ptrend = 0.005) scores, and perceived knowledge score was independently associated with a higher perceived ability score (β: 0.76 95%CI: 0.67, 0.84; ptrend = 0.04). The respondents mostly indicated concerns about government and corporate bodies' misuse of genomic data (35.7%) and the widening of socioeconomic disparities (34.0%). Although 65.0% of the respondents thought it important to learn about precision medicine, only 11.3% felt that their education had adequately prepared them for precision medicine, knew who to ask questions regarding genomic testing (10.7%) and felt their professors had encouraged the use of precision medicine (10.3%). Conclusion Our findings highlight gaps in preparedness for precision medicine and a need to improve precision medicine education among Nigerian medical students.